Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255251 | 0.82 | HCAR2 (0.56) | MEN1ALDH1A1PKMKMT2AHCAR2 | |
| SCHEMBL29892713 | 0.82 | HCAR2 (0.56) | MEN1ALDH1A1PKMKMT2AHCAR2 | |
| SCHEMBL13069279 | 0.76 | TNKS2 (0.59) | MEN1ALDH1A1KMT2APDE10ARAB9A | |
| SCHEMBL1623385 | 0.74 | PDE5A (0.44) | PDE5AHCAR2PDE10ARAB9A | |
| SCHEMBL1623229 | 0.73 | HCAR2 (0.69) | PDE5AKMT2AHCAR2PDE10A | |
| SCHEMBL1624581 | 0.67 | HCAR2 (0.74) | ALDH1A1KMT2AHCAR2MAPTHPGD | |
| SCHEMBL1624358 | 0.67 | HCAR2 (0.46) | PDE5AALDH1A1KMT2AHCAR2 | |
| SCHEMBL7404327 | 0.67 | PDE5A (1.00) | PDE5AMEN1ALDH1A1KMT2APDE10A | |
| SCHEMBL2894639 | 0.66 | CYP1B1 (0.48) | CYP1B1MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL2888208 | 0.66 | MEN1 (0.46) | CYP1B1MEN1ALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928106-B2 | 2-[2-(2,5-Difluoro-phenyl)-ethoxymethyl]-3H-pteridin-4-one; 2-2-(3-Fluoro-phenyl)-ethoxymethyl]-3H-pyrimido[4,5-d]pyrimidin-4-one; (5-Oxo-5,6-dihydro-pyrimido[4,5-c]pyridazin-7-ylmethyl)-carbamic acid benzyl ester, useful in treating diseases which are modulated by HM74A agonists e.g. dyslipidemia | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2139895-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116742-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | CHRM1, CHRM2, CHRM4 | PDE5A 339/4885CYP1B1 151/4885MEN1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.